Multiple Sclerosis News

• Less Frequent Dosing With MS Drug Safe With No Loss of Efficacy Patients with MS stable on natalizumab administered every 4 weeks may be able to safely switch to every-6-weeks dosing with no clinically meaningful loss of efficacy.
  Medscape Medical News, May 05, 2022
• Using MRI to Track Cerebral Damage in Multiple Sclerosis Data on repair or progression in normal-appearing brain tissue on conventional MRI.
  First Look, May 05, 2022
• Maternal Autoimmune Diseases Up Risk of Mental Illness in Children The risk of mental disorders was 16% higher in offspring whose mothers had autoimmune diseases such as diabetes and rheumatoid arthritis, a new study found.
  Medscape Medical News, May 03, 2022
• AAN 2022 Two MS Meds Tied to Higher COVID Rates A study of all MS patients in England taking a disease modifying therapy found higher infection and hospitalization rates in patients taking those drugs, even after COVID-19 vaccination.
  Medscape Medical News, April 28, 2022
• Roche Warns Multiple Sclerosis Drug Development Hit by Ukraine War Roche has warned that Russia's attack on Ukraine is disrupting the development of a new generation of multiple sclerosis drugs as the industry has come to disproportionately rely on Eastern Europe for clinical trials.
  Reuters Health Information, April 25, 2022
• Researchers Identify Potential Skin Biomarker for ALS TDP-43 protein, which is present in motor neurons in the brain and spinal cord of healthy individuals, was found in the dermis of patients with ALS.
  Medscape Medical News, April 22, 2022
• Peripheral Inflammation and Neurologic Symptoms in COVID-19 Using molecular analysis to characterize immunologic response in patients with COVID-19.
  First Look, April 20, 2022
• Childhood Abuse May Increase MS Risk in Adults Emotional or sexual abuse in childhood may increase risk for multiple sclerosis in women, and multiple kinds of abuse is tied to further risk, the first prospective study of its kind suggests.
  Medscape Medical News, April 20, 2022
• AACR 2022 Novel COVID-19 Vaccine for Patients With Blood Cancers A novel vaccine (CoVac-1) currently in clinical trials in Germany induced T-cell immune responses in a large proportion of patients with blood cancers and B cell deficiencies.
  Medscape Medical News, April 19, 2022
• OARSI 2022 High Comorbidity Rate Seen Before Osteoarthritis Diagnosis Since this was an explorative study, the results are "very interesting starting points for future research," said one of the investigators.
  Medscape Medical News, April 13, 2022
• AAN 2022 New Data Shed Light on Racial, Ethnic Diversity in MS Multiple sclerosis, sometimes thought of as primarily affecting White people, is also common and often more severe in Hispanic and Black people, a study assessing neighborhood-level data shows.
  Medscape Medical News, April 11, 2022
• A Faster, Cheaper Diagnostic Test for MS? A test that measures kappa in cerebrospinal fluid is faster, easier, and less costly for diagnosing multiple sclerosis than a more commonly used test, new research suggests.
  Medscape Medical News, April 08, 2022
• AAN 2022 Stem Cells Restore Lost Function in Traumatic Brain Injury For the first time, stem cell therapy has been shown to improve disability caused by moderate to severe traumatic brain injury.
  Medscape Medical News, April 07, 2022
• Antibiotic Use in Midlife Ups Risk of Cognitive Decline Prolonged consumption of antibiotic may have negative effects on cognition comparable to those caused by 3 to 4 years of aging.
  Medscape Medical News, April 01, 2022
• NP-led Care Improves Quality of Life for Multiple Sclerosis Patients In a randomized trial, depression improved compared to usual neurologist care.
  First Look, March 18, 2022
• ACTRIMS 2022 Does MS Drug Dosing Regimen Need Revising? B cell depletion can last well past the 6-month dosing regimen typically used with ocrelizumab or rituximab for multiple sclerosis or neuromyelitis optica spectrum disorders, new research suggests.
  Medscape Medical News, March 15, 2022
• ACTRIMS 2022 Early MS Biomarkers May Improve Prediction of Long-term Outcomes Serum neurofilament light chain and glial fibrillary acidic protein levels can help improve outcome predictions in multiple sclerosis — and are linked to relapse risk after treatment discontinuation.
  Medscape Medical News, March 10, 2022
• Smoking, Drinking Tied to Increased MS Risk, More Severe Symptoms High alcohol consumption can contribute to more severe neurodegeneration in multiple sclerosis — and smoking may increase risk for disease development, new research suggests.
  Medscape Medical News, March 10, 2022
• AAN 2022 Keto Diet in MS Tied to Less Disability, Better Quality of Life Consumption of a ketogenic diet is safe — and may help reduce disability and improve fatigue and depressive symptoms in patients with relapsing multiple sclerosis (MS), new research suggests.
  Medscape Medical News, March 10, 2022
• Modeling of Individual Neurophysiologic Brain Connectivity Researchers demonstrated individual functional connectivity patterns using structural data from weighted imaging and magnetoencephalography to predict neurologic disease trajectories.
  First Look, March 10, 2022